Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.56 |
| ▸ | TTK | P33981 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34463566 | 0.87 | TTK (0.59) | ALKTTK | |
| SCHEMBL16514067 | 0.86 | ALK (0.66) | ALKTTKEGFR | |
| SCHEMBL29847756 | 0.82 | TTK (0.63) | ALKTTKEGFRIGF1R | |
| SCHEMBL16514796 | 0.82 | TTK (0.63) | ALKTTKEGFRIGF1R | |
| SCHEMBL16514212 | 0.80 | TTK (0.59) | ALKTTKEGFR | |
| SCHEMBL16513799 | 0.79 | TTK (0.75) | ALKTTKEGFRIGF1R | |
| SCHEMBL29847169 | 0.79 | TTK (0.75) | ALKTTKEGFRIGF1R | |
| SCHEMBL25259557 | 0.77 | EGFR (0.66) | ALKEGFRIGF1R | |
| SCHEMBL16513556 | 0.73 | TTK (0.62) | ALKTTKEGFR | |
| SCHEMBL16769548 | 0.72 | ALK (1.00) | ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | ALK 441/4885TTK 2/4885EGFR 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.